Predicting the Behaviour of Cell Clones

bioprod no background guest blog

This week our blog post comes courtesy of Professor Nicolas Mermod, Director Institute of Biotechnology, University of Lausanne, who is speaking on Track 1, Day 1 at 15.05

How to improve the methods for identifying and predicting the behaviour of cell clones before going into scale-up?

As part of one of most upstream steps of the pharmaceutical process, the industry has to screen hundreds of cell lines to identify the suitable clone to find one that displays the required properties. However, there is no tool which will allow you to predict reliably what the behaviour of the cell clone will be once in the bioreactor. There is a need for the industry to have one simple measurement or set of tools which will allow you to see if the clone will behave well. I hope that the combination of genome, transcriptome and proteome data associated to a particular clone will provide more predictive and reliable descriptions of their behaviour in a bioreactor.

The main question still asked is: What are the relevant parameters? This is the main question and we are not there yet

Please attend the talks from Professor Nicolas Mermod, Professor Martin Clynes, Dr Niall Barron and Professor Mark Smales who should all be touching on this important challenge at BioProduction 2013

The nature and fate of HCPs

“The analytical technologies available for the monitoring of product- and process-related impurities in recombinant protein preparations have developed enormously in the last 10-20 years. However, these have not yet been fully harnessed to generate a complete picture of the mechanisms determining process and product impurities.”


The nature and fate of HCPs during downstream processing remains poorly characterised. At BioProduction this autumn, hear Professor Mark Smales from University of Kent discuss his findings of a proteomic approach for investigating the dynamics and fate of HCPs. He will reveal how these results and the knowledge gained can be used to screen cell lines or hosts to select those with reduced HCP profiles.

If you’d like more information about HCPs, CHO cells, antibody purification processes or mAbs then please visit the downloads section of our website for links to related articles

Discovering the role of miRNAs

Interested in the advancements made in cell engineering to improve bioprocessing?

Looking for methods to increase the efficiency and fast track your upstream process whilst ensuring raw materials and quality of biopharmaceuticals?

Then read on for more information and industry findings on RNAs and cell line characteristics.

At this year’s BioProduction, Dr Niall Barron, Dublin City University, will be sharing his findingsĀ  on how non-coding RNAs are used as tools to improve cell line characteristics. His talk will be looking at the advances made in characterising their role in CHO cells and how this can be used as a potential engineering tool to improve recombinant protein production.

In his recent paper, Dr Barron touches on these findings and looks at the analysis of a range of CHO cell clones in order to discover the role of miRNAs in growth rate variation, which will then enable the biopharm industry to prioritise a number of potential miRNA cell engineering candidates.

Want more information on this topic? Then visit our website

Coming next week, a piece on the nature and fate of HCPs during downstream processing

An Insight from Mark Uden, GSK

interviewWe recently caught up with Mark Uden, Head of Biopharm Process Research, at GSK to ask him a few questions about his presentation and how he thinks the industry will change over the next few years….

BioProduction (BP): Can you please give a brief overview of your key research interests?

Mark Uden (MU): The design and de-risking of quality Biopharmaceuticals fit for industrialisation

BP: What can industry gain from this?

MU: Accelerated timelines with the right molecuar APIs

BP: And what work will you be presenting at the 2013 BioProduction conference?

MU: How we systematically dissect and understand lead biopharmaceutical prior to candidate selection and full development

BP: What will delegates gain by attending your presentation and session? What is the message you would like them to leave with?

MU: Invest early in understanding Biopharm lead molecules – a stitch in time saves nine

BP: What is the No 1 challenge facing the bioprocessing industry at the moment?

MU: COGs and development timelines reductions is the perennial challenge for us all in Biopharms

BP: What was the last “breakthrough” technology you either bought or used?

MU: Aside from some low-volume, high throughput bespoke automation, I think over the last few years the introduction of SUBs have been good; escaping rigid SIP set-ups makes life a lot simpler

BP: How will the industry look in 2-3 years? What challenges will still remain/would have been overcome?

MU: In process development, I’m seeing more and more interest in automated microscale highthroughput bioreactor rigs for process development and validation

BP: What other sessions/talks are you interested in attending at this year’s BioProduction 2013?

MU: I’m always partial to the Analytical/Comparability talks – some of those look good and so I’ll be looking out for them. Plus those describing novel architectures always interest me too.

BP: Are there any articles that you would recommend the audience follow that relates to your subject area?

MU: Too many to list here – I do still like that 2011 Nature Biotech paper entitled “Acceptable changes in quality attributes of flycosylated biopharmaceuticals” – it was quite thought provoking

BP: And finally, on a more relaxed note, what did you want to be when you were young?

MU: A deep sea diver or soccer player

Thanks to Mark Uden for his insights into biopharmaceuticals and the changes he thinks are coming to the industry – for more information about Mark’s presentation, or any of our expert-led talks this year, please visit our website